A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers

被引：0
作者：
Takashi Eto
Yuji Karasuyama
Verónica González
Ana Del Campo García
机构：
[1] Souseikai Hakata Clinic,Clinical Research Unit
[2] Syneos Health Clinical K.K.,Medical Department
[3] mAbxience Research S.L.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 88卷
关键词：
MB02; Bevacizumab; Biosimilars; Pharmacokinetics; Safety; Japanese;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：713 / 722
页数：9
相关论文
共 50 条
  • [31] Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects
    Chow, Vincent
    Oh, MyungShin
    Gessner, Melissa A.
    Fanjiang, Gary
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 246 - 255
  • [32] A randomized, double-blind, parallel-group, single-dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men
    Singh, Inderjeet
    Patel, Ronak
    Patel, Akash
    Jose, Vinu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 193 - 202
  • [33] A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers
    Jamshidi, Ahmadreza
    Sabzvari, Araz
    Anjidani, Nassim
    Shahpari, Ramin
    Badri, Nima
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 327 - 331
  • [34] Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers
    Lissy, Michael
    Stiff, Dwight D.
    Kowalski, Mark M.
    Moore, Keith A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (10) : 2423 - 2428
  • [35] Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers
    Fok, Benny S. P.
    Gardner, Stephen
    Piscitelli, Steve
    Chen, Shuguang
    Chu, Tanya T. W.
    Chan, Jones C. M.
    Tomlinson, Brian
    CLINICAL THERAPEUTICS, 2013, 35 (01) : 68 - 76
  • [36] A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects
    Pivot, Xavier
    Curtit, Elsa
    Lee, Yoon Jung
    Golor, George
    Gauliard, Anke
    Shin, Donghoon
    Kim, Youngdoe
    Kim, Hansook
    Fuhr, Rainard
    CLINICAL THERAPEUTICS, 2016, 38 (07) : 1665 - 1673
  • [37] A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment
    Bramson, C
    Ouellet, D
    Roman, D
    Randinitis, E
    Gardner, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (01) : 29 - 36
  • [38] A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of two formulations of metformin in healthy volunteers
    Noh, Yook-Hwan
    Lim, Hyeong-Seok
    Jung, Jin Ah
    Jin, Seok-Joon
    Kim, Mi Jo
    Kim, Yo Han
    Park, Hyun-Jung
    Bae, Kyun-Seop
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (08) : 605 - 613
  • [39] A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust®, and reference trastuzumab in healthy subjects
    Farahani, Mohammad Farmahini
    Maghzi, Parnian
    Aryan, Nazanin Jafari
    Payandemehr, Borna
    Soni, Mayur
    Azhdarzadeh, Morteza
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1443 - 1450
  • [40] A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects
    Liu, Zhengzhi
    Gao, Zhenyue
    Yang, Wei
    Zhang, Lixiu
    Xiao, Nan
    Qu, Dongmei
    Su, Zhengjie
    Xu, Kaibo
    Liu, Guangwen
    Wang, Yanli
    Ren, Qing
    Yu, Shuang
    Cheng, Yang
    Zhou, Yannan
    Deng, Qiaohuan
    Zhao, Yicheng
    Wang, Zeyu
    Yang, Haimiao
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2022, 18 (7-8) : 519 - 527
12345